Fri, November 16, 2012
Thu, November 15, 2012
Wed, November 14, 2012
Tue, November 13, 2012
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
[ Wed, Nov 07th 2012 ]: Market Wire
AtheroNova Names New Director
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012

HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast

  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. -annual-healthcare-conference-to-be-webcast.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare... -- FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ --

FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: [ HTWR ] - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference at 10:00 a.m. EST on Tuesday, November 13, 2012.  The conference is being held November 13-14, 2012, at The Pierre Hotel in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at [ www.heartware.com ].  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit [ www.heartware.com ].

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: [ ctaylor@heartwareinc.com ]
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.



RELATED LINKS
[ http://www.heartware.com ]